pharmaphorum3y
FDA okays ViiV's Apretude as first injectable for HIV PrEP
GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP ...
MM&M11d
ViiV Healthcare wants to help patients, HCPs navigating HIV in video series
ViiV Healthcare understands this push-and-pull dynamic all too well and sought out to do something about it. “Both sides are waiting for the other person to initiate and take the lead in those deeper ...
Hosted on MSN18d
ViiV Healthcare and J&J’s adolescent HIV-1 combo gains EC authorisation
The European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus Rekambys (rilpivirine long-acting injections) from Johnson & Johnson ...
pharmaphorum1y
China clears ViiV, J&J injectable HIV treatment
ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep the virus at bay. China’s ...
Yahoo Finance8d
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
ViiV Healthcare is committed to ensuring timely public access for APRETUDE to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by ...